Valaciclovir
- Generic Name
- Valaciclovir
- Brand Names
- Valtrex
- Drug Type
- Small Molecule
- Chemical Formula
- C13H20N6O4
- CAS Number
- 124832-26-4
- Unique Ingredient Identifier
- MZ1IW7Q79D
- Background
Valaciclovir (valacyclovir), also known as Valtrex, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It is a member of the purine (guanine) nucleoside analog drug class ...
- Indication
Valacyclovir is a nucleoside analog DNA polymerase inhibitor indicated for :
Adults
• Cold Sores (Herpes Labialis)
• Genital Herpes
• Treatment of genital herpes lesions in immunocompetent patients (initial or recurrent episode)
• Suppression of genital herpes lesions in immunocompetent or HIV-infected patients
• Reduction of viral transmission
...
- Associated Conditions
- Chickenpox, Genital Herpes, Genital herpes, initial episode, Herpes Labialis, Herpes Zoster, Recurrent Genital Herpes (RGH)
- Associated Therapies
- Suppression of Recurrent Genital Herpes (RGH)
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 60
- Registration Number
- NCT03541928
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Anti-viral Therapy in Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 120
- Registration Number
- NCT03282916
- Locations
- 🇺🇸
Banner Alzheimer's Institute (BAI), Phoenix, Arizona, United States
🇺🇸New York University School of Medicine, New York, New York, United States
🇺🇸New York State Psychiatric Institute, New York, New York, United States
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
- Conditions
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 57
- Registration Number
- NCT03004183
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Eric Bernicker, MD
- Target Recruit Count
- 11
- Registration Number
- NCT02831933
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
- Conditions
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 187
- Registration Number
- NCT02768363
- Locations
- 🇺🇸
Foothills Urology, Golden, Colorado, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸Allegheny Health Network-Triangle Urological Group, Pittsburgh, Pennsylvania, United States
Should We Use Oral Valacyclovir in Acute Herpetic Gingivostomatitis in Children?
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- St. Justine's Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT02738229
- Locations
- 🇨🇦
CHU Sainte-Justine, Montreal, Quebec, Canada
HSV529 Vaccine in HSV-2 Seropositive Adults
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT02571166
- Locations
- 🇺🇸
University of Washington Virology Research Clinic, Seattle, Washington, United States
A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia
- Conditions
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- ContraVir Pharmaceuticals, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT02412917
- Locations
- 🇺🇸
TX, Webster, Texas, United States
Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT02351102
- Locations
- 🇮🇱
Helen Schneider Hospital for Women, Petah Tikva, Israel
Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT02226978
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.